Data / Form D filings / Orbsen Therapeutics Ltd.
Orbsen Therapeutics Ltd.: Form D filing
Orbsen Therapeutics Ltd., a biotechnology company in Galway, Ireland, filed a Form D with the SEC in 2017. The latest, on July 26, 2017, reports $1.3 million sold of a $3.7 million offering to 11 investors.
Find out what Orbsen Therapeutics Ltd. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- ORBSEN BUILDING, NATIONAL UNIVERSITY OF IRELAND, GALWAY, Galway, Ireland, H91DK
- Phone
- 353 91 528778
- Industry
- Biotechnology
- Entity type
- Limited Liability Company
- Incorporated in
- Ireland
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1712617
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jul 26, 2017 | New notice | $3,690,600 | $1,257,491 | $2,433,109 | 11 | Jan 19, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Francis Barry | Executive Officer, Director | |
| Gerry Cuddy | Director | |
| Jack Kavanaugh | Director | |
| Jim Fahy | Director | |
| Chris Coughlan | Director | |
| Timothy O'Brien | Director | |
| Larry Couture | Executive Officer, Director | |
| Scott Tornblom | Director |
Every Form D from the week of Jul 24, 2017 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Orbsen Therapeutics Ltd. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.